Jeffrey P. Kushan

I'll research this attorney's background before drafting.

Jeffrey P. Kushan — Sidley Austin LLP (Washington, D.C.)

Kushan is a partner at Sidley Austin, where he serves as global coordinator of the firm's national IP litigation practice. His practice centers on patent litigation, Federal Circuit appeals, and contested proceedings before the PTAB, with a life-sciences core (biologics under the BPCIA, Hatch-Waxman pharmaceutical and biosimilar disputes) alongside consumer electronics, software, and industrial biotechnology work. The tracked docket reflects that range: biologics/enzyme patent disputes such as Merck Sharp & Dohme v. Halozyme and the Amgen/Enbrel biosimilar litigation, on the life-sciences side, and VirnetX v. Apple, Nintendo v. Resonant Systems, and Linfo IP v. Vuori on the electronics and NPE-defense side.

On side preference, his tracked appearances are evenly split (4 plaintiff-side, 4 defendant-side), and the mix is consistent with the profile of a first-chair adviser to innovator companies rather than a repeat NPE/PAE plaintiffs' firm: he prosecutes/asserts patents for innovator life-sciences clients (GE Healthcare v. Johns Hopkins; Merck v. Halozyme) and simultaneously defends large operating companies against patent owners, most visibly Apple in the VirnetX IPR campaign and Nintendo against Resonant Systems' haptic/vibration patents. Publicly described as representing "innovator companies" in BPCIA and Hatch-Waxman matters; no evidence of a PAE-plaintiff practice.

PTAB/IPR experience. This is a substantial part of his practice, not a sideline. Sidley's and Chambers' profiles state he has been lead counsel in more than 225–250 PTAB proceedings and has argued before the Board more than 25 times; Sidley's practice descriptions note he regularly acts as lead counsel in PTAB proceedings, and he has handled related appeals at the Federal Circuit. Representative PTAB work includes the VirnetX IPRs for Apple, the Merck/Halozyme PGR series (PGR2025-00003 and related filings, where he is lead counsel), GE Healthcare's IPR and PGR challenges to Johns Hopkins patents (IPR2025-00808 terminated on settlement before institution; a related petition was instituted in 2026), and Nintendo's IPRs against Resonant Systems (one proceeding resolved by settlement; another reached a final written decision finding claims unpatentable, now on appeal by the patent owner).

Notable results and background. Kushan argued for Apple in Apple v. Omni Medsci (Fed. Cir. 2024), where the court vacated the Board's decision in part and remanded, and was counsel of record for Apple in VirnetX Inc. v. Apple Inc., 909 F.3d 1375 (Fed. Cir. 2018), which affirmed PTAB findings that claims of the '696 patent were unpatentable as obvious. Public reporting credits the Sidley team including Kushan with Amgen's win in the long-running Enbrel biosimilar dispute (2019). Before private practice he served at the USPTO and as chief U.S. negotiator at USTR in Geneva for the 1996 WIPO "Internet" treaties. Bar admissions listed in his congressional testimony and Sidley materials: District of Columbia, Virginia, U.S. Supreme Court, Federal Circuit, E.D. Va., and the USPTO (Reg. No. 43,401); J.D., George Washington University (1992, with honors); M.A. in chemistry, UNC–Chapel Hill (1987); B.S. in chemistry, William & Mary (1985).

Note on sourcing: all tracked appearances and firm-identifying records show Sidley Austin; I found no reliable public record of a prior law firm employer, so none is stated. Two tracked matters are unidentified in the source data, so their subject matter is not characterized here.